Quote | CYBIN INC. (AQNC:CYBN:CC)
Last: | $0.67 |
---|---|
Change Percent: | -1.47% |
Open: | $0.67 |
Close: | $0.67 |
High: | $0.68 |
Low: | $0.64 |
Volume: | 67,599 |
Last Trade Date Time: | 05/06/2022 04:52:03 pm |
News | CYBIN INC. (AQNC:CYBN:CC)
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options. The company has provided a corporate update highlighting recent clinical ...
- Recent U.S. $150 Million funding round lead by a syndicate of leading biopharmaceutical institutional investors supports advancement of clinical-stage programs CYB003 and CYB004 - - Received U.S. Food and Drug Administration (“FDA”) Breakthrough Therapy Designation (ȁ...
Message Board Posts | CYBIN INC. (AQNC:CYBN:CC)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
CYBIN INC. Company Name:
CYBN:CC Stock Symbol:
AQNC Market:
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options. The company has provided a corporate update highlighting recent clinical ...
- Recent U.S. $150 Million funding round lead by a syndicate of leading biopharmaceutical institutional investors supports advancement of clinical-stage programs CYB003 and CYB004 - - Received U.S. Food and Drug Administration (“FDA”) Breakthrough Therapy Designation (ȁ...
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, is announcing its participation at the 27th Annual Milken Institute Global Conference, set to take place May 5-8, 2024, at th...